Hetero[3.1.1]propellanes

Edward Anderson,Rebecca Revie,Ayan Dasgupta,Yasmine Biddick,Kirsten Christensen,Russell Smith
DOI: https://doi.org/10.26434/chemrxiv-2024-tnx0l
2024-12-31
Abstract:[n.1.1]Propellanes are molecules featuring a carbon-carbon bond to which three rings are fused, two being cyclopropanes. [1.1.1] and [3.1.1]propellane are key precursors to small-ring bridged bicyclic hydrocarbons, motifs that have emerged as important building blocks in contemporary drug design. Due to their rigid frameworks and well-defined substituent vectors, these bicyclic hydrocarbons can serve as bioisosteres for disubstituted benzene rings, exhibiting improved metabolic stability compared to their aromatic parents, while also bringing benefits to solubility and other physicochemical properties. Unknown to date are [n.1.1]propellanes featuring heterocyclic rings, molecules that could enable the direct and rapid synthesis of a wide diversity of bridged bicyclic heterocycles, which should exhibit superior physicochemical profiles compared to their carbocyclic analogues while also introducing additional functionality for potential interactions with molecular targets. Here we report the unified synthesis of a family of heterocyclic [3.1.1]propellanes featuring oxygen, nitrogen and sulfur heteroatoms in the three-carbon bridge. The approaches we developed are necessarily distinct from the established route to carbocyclic propellanes, and utilise a common precursor that is conveniently assembled on multigram scale via a rhodium-catalysed cyclopropanation. We found that these hetero[3.1.1]propellanes are stable towards isolation and storage, but amenable to a range of radical ring-opening reactions, leading to bridgehead-disubstituted hetero-bicyclo[3.1.1]heptanes that cannot be accessed using alternative methods. Given the importance of heterocyclic scaffolds in pharmaceutical design, and the ever-growing popularity of rigid small ring building blocks, we expect these unprecedented hetero-propellanes will be of exceptional utility in drug discovery programmes
Chemistry
What problem does this paper attempt to address?